​

Inspire Medical Systems (INSP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INSP Stock Forecast

Inspire Medical Systems stock forecast is as follows: an average price target of $223.17 (represents a 18.70% upside from INSP’s last price of $188.01) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

INSP Price Target

The average price target for Inspire Medical Systems (INSP) is $223.17 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $260.00 to $170.00. This represents a potential 18.70% upside from INSP's last price of $188.01.

INSP Analyst Ratings

Buy

According to 9 Wall Street analysts, Inspire Medical Systems's rating consensus is 'Buy'. The analyst rating breakdown for INSP stock is 0 'Strong Buy' (0.00%), 6 'Buy' (66.67%), 3 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Inspire Medical Systems Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Adam MaederPiper Sandler$260.00$199.0030.65%38.29%
Nov 05, 2024David RescottRobert W. Baird$252.00$199.0026.63%34.04%
Oct 15, 2024David RescottRobert W. Baird$240.00$210.4614.04%27.65%
Jul 29, 2024Michael SarconeJefferies$230.00$129.7977.21%22.33%
Jul 16, 2024Richard NewitterTruist Financial$217.00$138.5856.59%15.42%
Jul 15, 2024Kallum TitchmarshMorgan Stanley$210.00$138.8951.20%11.70%
Jun 25, 2024Adam MaederPiper Sandler$255.00$139.4082.93%35.63%
Jun 24, 2024Jonathan BlockStifel Nicolaus$170.00$162.464.64%-9.58%
Jun 11, 2024Paige MeyerCFRA$175.00$166.315.22%-6.92%
Apr 19, 2024Shagun SinghRBC Capital$285.00$241.1518.18%51.59%
Mar 19, 2024Kallum TitchmarshMorgan Stanley$250.00$204.4522.28%32.97%
Feb 08, 2023J.P. Morgan$300.00$249.5820.20%59.57%
Dec 20, 2022Truist Financial$308.00$248.8123.79%63.82%
Aug 03, 2022Piper Sandler$285.00$216.8331.44%51.59%
Jun 10, 2022Richard NewitterTruist Financial$250.00$186.3934.13%32.97%
May 04, 2022Adam MaederPiper Sandler$310.00$213.5645.16%64.88%
Mar 03, 2022Travis SteedBank of America Securities$270.00$238.8013.07%43.61%
Apr 29, 2021Kyle BauserColliers Securities$266.00$240.6810.52%41.48%

The latest Inspire Medical Systems stock forecast, released on Nov 05, 2024 by Adam Maeder from Piper Sandler, set a price target of $260.00, which represents a 30.65% increase from the stock price at the time of the forecast ($199.00), and a 38.29% increase from INSP last price ($188.01).

Inspire Medical Systems Price Target by Period

1M3M12M
# Anlaysts-311
Avg Price Target-$250.67$231.27
Last Closing Price$188.01$188.01$188.01
Upside/Downside-100.00%33.33%23.01%

In the current month, the average price target of Inspire Medical Systems stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Inspire Medical Systems's last price of $188.01. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 20, 2024Bank of America SecuritiesNeutralBuyUpgrade
Sep 30, 2024Truist FinancialMarket PerformMarket PerformHold
Sep 10, 2024RBC CapitalMarket PerformMarket PerformHold
Jul 29, 2024JefferiesBuyBuyHold
Jul 15, 2024Morgan StanleyOverweightOverweightHold
Jun 25, 2024Piper SandlerOverweightOverweightHold
Jun 24, 2024RBC CapitalBuyBuyHold
Jun 11, 2024CFRAHoldHoldHold
Jun 03, 2024RBC CapitalBuyBuyHold
Jun 03, 2024Bank of America SecuritiesNeutralNeutralHold
May 23, 2024OppenheimerPerformPerformHold
Apr 19, 2024Truist FinancialBuyBuyHold
Apr 19, 2024RBC CapitalOutperformInitialise
Jun 08, 2023Piper SandlerOverweightOverweightHold
Feb 08, 2023Piper SandlerOverweightOverweightHold
Dec 13, 2022CitigroupOverweightInitialise
Dec 13, 2022Goldman SachsBuyUpgrade
Aug 03, 2022Piper SandlerOverweightOverweightHold

Inspire Medical Systems's last stock rating was published by Bank of America Securities on Nov 20, 2024. The company Upgrade its INSP rating from "Neutral" to "Buy".

Inspire Medical Systems Financial Forecast

Inspire Medical Systems Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$153.30M$151.09M$127.90M$137.90M$109.19M$91.39M$69.38M$78.40M$61.69M$52.96M$40.35M$46.01M$35.84M$12.18M$21.35M$26.91M$20.86M
Avg Forecast$322.96M$281.18M$277.27M$243.78M$277.81M$240.43M$233.03M$199.48M$233.04M$197.59M$189.08M$161.41M$186.75M$154.49M$136.47M$120.06M$131.07M$94.31M$78.46M$64.17M$74.61M$55.62M$43.87M$36.94M$41.67M$22.69M$7.85M$21.32M$23.84M$19.14M
High Forecast$330.94M$288.12M$284.12M$249.80M$284.67M$246.36M$238.79M$205.55M$234.33M$197.64M$189.08M$161.41M$186.81M$162.27M$139.84M$123.03M$134.31M$94.31M$78.46M$64.17M$74.61M$55.62M$43.87M$36.94M$41.67M$22.69M$7.85M$21.32M$23.84M$19.14M
Low Forecast$315.41M$274.60M$270.79M$238.08M$271.31M$234.80M$227.58M$195.63M$231.51M$197.54M$189.08M$161.41M$186.74M$148.34M$133.28M$117.26M$128.01M$94.31M$78.46M$64.17M$74.61M$55.62M$43.87M$36.94M$41.67M$22.69M$7.85M$21.32M$23.84M$19.14M
# Analysts5454434812644513665551112111091377986
Surprise %-------------0.99%1.11%1.07%1.05%1.16%1.16%1.08%1.05%1.11%1.21%1.09%1.10%1.58%1.55%1.00%1.13%1.09%

Inspire Medical Systems's average Quarter revenue forecast for Dec 23 based on 5 analysts is $186.75M, with a low forecast of $186.74M, and a high forecast of $186.81M. INSP's average Quarter revenue forecast represents a 21.82% increase compared to the company's last Quarter revenue of $153.30M (Sep 23).

Inspire Medical Systems EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434812644513665551112111091377986
EBITDA-------------$-13.47M$-16.60M$-15.21M$3.27M$-15.43M$-13.44M$-15.71M$-1.49M$-9.47M$-12.23M$-15.44M$-6.67M$-9.55M$-22.38M$-15.53M$-8.36M$-7.58M
Avg Forecast$-71.87M$-62.57M$-61.70M$-54.25M$-61.82M$-53.50M$-51.86M$-44.39M$-51.86M$-43.97M$-42.07M$-23.52M$-41.56M$-34.38M$-30.37M$-21.38M$-2.67M$-22.54M$-18.75M$-19.44M$-17.83M$-13.29M$-10.48M$-16.84M$-9.96M$-5.42M$-1.88M$-12.81M$-5.70M$-4.57M
High Forecast$-70.19M$-61.11M$-60.26M$-52.98M$-60.37M$-52.25M$-50.64M$-43.53M$-51.52M$-43.96M$-42.07M$-18.82M$-41.55M$-33.01M$-29.66M$-17.11M$-2.13M$-22.54M$-18.75M$-15.55M$-17.83M$-13.29M$-10.48M$-13.47M$-9.96M$-5.42M$-1.88M$-10.25M$-5.70M$-4.57M
Low Forecast$-73.64M$-64.11M$-63.22M$-55.59M$-63.35M$-54.82M$-53.14M$-45.74M$-52.14M$-43.98M$-42.07M$-28.22M$-41.57M$-36.11M$-31.12M$-25.66M$-3.20M$-22.54M$-18.75M$-23.33M$-17.83M$-13.29M$-10.48M$-20.21M$-9.96M$-5.42M$-1.88M$-15.37M$-5.70M$-4.57M
Surprise %-------------0.39%0.55%0.71%-1.23%0.68%0.72%0.81%0.08%0.71%1.17%0.92%0.67%1.76%11.92%1.21%1.47%1.66%

6 analysts predict INSP's average Quarter EBITDA for Mar 23 to be $-21.38M, with a high of $-17.11M and a low of $-25.66M. This is -752.90% lower than Inspire Medical Systems's previous annual EBITDA (Dec 22) of $3.27M.

Inspire Medical Systems Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434812644513665551112111091377986
Net Income-------------$-8.54M$-11.95M$-15.42M$3.15M$-16.85M$-14.49M$-16.69M$-2.39M$-10.35M$-13.09M$-16.22M$-7.48M$-10.38M$-23.09M$-16.25M$-9.08M$-8.25M
Avg Forecast$40.21M$28.07M$23.65M$6.25M$32.89M$18.06M$13.13M$-3.87M$21.98M$1.88M$-4.28M$-25.00M$-1.64M$-17.77M$-17.45M$-22.72M$-4.28M$-22.98M$-18.51M$-20.66M$-13.30M$-18.69M$-19.49M$-17.69M$-13.94M$-21.94M$-33.62M$-13.39M$-12.20M$-12.55M
High Forecast$41.51M$28.97M$24.40M$6.45M$33.95M$18.64M$13.56M$3.87M$23.50M$1.94M$-4.15M$-20.00M$7.37M$-11.33M$-16.92M$-18.18M$-3.42M$-22.98M$-18.51M$-16.53M$-13.30M$-18.69M$-19.49M$-14.15M$-13.94M$-21.94M$-33.62M$-10.72M$-12.20M$-12.55M
Low Forecast$38.99M$27.21M$22.93M$6.06M$31.89M$17.51M$12.73M$-12.76M$21.06M$1.83M$-4.42M$-30.00M$-14.33M$-24.51M$-18.01M$-27.27M$-5.14M$-22.98M$-18.51M$-24.79M$-13.30M$-18.69M$-19.49M$-21.23M$-13.94M$-21.94M$-33.62M$-16.07M$-12.20M$-12.55M
Surprise %-------------0.48%0.69%0.68%-0.74%0.73%0.78%0.81%0.18%0.55%0.67%0.92%0.54%0.47%0.69%1.21%0.74%0.66%

Inspire Medical Systems's average Quarter net income forecast for Mar 23 is $-22.72M, with a range of $-27.27M to $-18.18M. INSP's average Quarter net income forecast represents a -821.42% decrease compared to the company's last Quarter net income of $3.15M (Dec 22).

Inspire Medical Systems SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434812644513665551112111091377986
SG&A-------------$113.25M$112.62M$101.99M$94.83M$85.60M$76.69M$63.56M$58.77M$53.24M$48.70M$41.91M$38.63M$33.22M$26.98M$29.05M$28.19M$22.43M
Avg Forecast$296.39M$258.04M$254.46M$223.72M$254.95M$220.64M$213.86M$183.06M$213.86M$181.33M$173.52M$95.18M$171.38M$141.78M$125.24M$86.53M$105.22M$86.55M$72.01M$58.89M$68.47M$51.04M$40.26M$33.90M$38.24M$20.82M$7.21M$19.57M$21.88M$17.56M
High Forecast$303.71M$264.41M$260.74M$229.24M$261.24M$226.09M$219.14M$188.63M$215.05M$181.38M$173.52M$114.21M$171.44M$148.92M$128.33M$103.83M$126.27M$86.55M$72.01M$58.89M$68.47M$51.04M$40.26M$33.90M$38.24M$20.82M$7.21M$19.57M$21.88M$17.56M
Low Forecast$289.46M$252.01M$248.51M$218.49M$248.99M$215.48M$208.86M$179.53M$212.46M$181.28M$173.52M$76.14M$171.38M$136.13M$122.31M$69.22M$84.18M$86.55M$72.01M$58.89M$68.47M$51.04M$40.26M$33.90M$38.24M$20.82M$7.21M$19.57M$21.88M$17.56M
Surprise %-------------0.80%0.90%1.18%0.90%0.99%1.07%1.08%0.86%1.04%1.21%1.24%1.01%1.60%3.74%1.48%1.29%1.28%

Inspire Medical Systems's average Quarter SG&A projection for Dec 23 is $171.38M, based on 5 Wall Street analysts, with a range of $171.38M to $171.44M. The forecast indicates a 51.34% rise compared to INSP last annual SG&A of $113.25M (Sep 23).

Inspire Medical Systems EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434812644513665551112111091377986
EPS-------------$-0.29$-0.41$-0.53$0.11$-0.60$-0.53$-0.61$-0.09$-0.38$-0.48$-0.60$-0.28$-0.39$-0.88$-0.67$-0.38$-0.34
Avg Forecast$1.31$0.92$0.77$0.20$1.07$0.59$0.43$-0.13$0.72$0.06$-0.14$-0.65$-0.05$-0.58$-0.57$-0.66$-0.61$-0.76$-0.61$-0.80$-0.44$-0.61$-0.64$-0.66$-0.46$-0.72$-1.11$-0.59$-0.40$-0.41
High Forecast$1.35$0.95$0.80$0.21$1.11$0.61$0.44$0.13$0.77$0.06$-0.14$-0.63$0.24$-0.37$-0.55$-0.64$-0.59$-0.76$-0.61$-0.80$-0.44$-0.61$-0.64$-0.66$-0.46$-0.72$-1.11$-0.59$-0.40$-0.41
Low Forecast$1.27$0.89$0.75$0.20$1.04$0.57$0.42$-0.42$0.69$0.06$-0.14$-0.67$-0.47$-0.80$-0.59$-0.68$-0.63$-0.76$-0.61$-0.80$-0.44$-0.61$-0.64$-0.66$-0.46$-0.72$-1.11$-0.59$-0.40$-0.41
Surprise %-------------0.50%0.72%0.80%-0.18%0.79%0.87%0.77%0.20%0.62%0.75%0.91%0.61%0.54%0.80%1.14%0.95%0.82%

According to 6 Wall Street analysts, Inspire Medical Systems's projected average Quarter EPS for Mar 23 is $-0.66, with a low estimate of $-0.68 and a high estimate of $-0.64. This represents a -700.26% decrease compared to INSP previous annual EPS of $0.11 (Dec 22).

Inspire Medical Systems Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
OMOutset Medical$1.01$3.00197.03%Buy
TMDXTransMedics Group$65.71$116.3377.04%Buy
TNDMTandem Diabetes Care$34.23$51.4350.25%Buy
DXCMDexCom$77.80$104.5034.32%Buy
INMDInMode$17.83$21.7521.99%Hold
INSPInspire Medical Systems$190.71$223.1717.02%Buy
NARIInari Medical$56.16$64.0013.96%Buy
GMEDGlobus Medical$83.42$85.001.89%Buy
PODDInsulet$263.35$268.001.77%Buy
GKOSGlaukos$146.35$144.14-1.51%Buy
NVCRNovoCure$32.10$30.00-6.54%Hold
PENPenumbra$247.55$230.25-6.99%Buy
CLPTClearPoint Neuro$16.34$15.00-8.20%Buy

INSP Forecast FAQ

Is Inspire Medical Systems a good buy?

Yes, according to 9 Wall Street analysts, Inspire Medical Systems (INSP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 66.67% of INSP's total ratings.

What is INSP's price target?

Inspire Medical Systems (INSP) average price target is $223.17 with a range of $170 to $260, implying a 18.70% from its last price of $188.01. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Inspire Medical Systems stock go up soon?

According to Wall Street analysts' prediction for INSP stock, the company can go up by 18.70% (from the last price of $188.01 to the average price target of $223.17), up by 38.29% based on the highest stock price target, and down by -9.58% based on the lowest stock price target.

Can Inspire Medical Systems stock reach $300?

INSP's average twelve months analyst stock price target of $223.17 does not support the claim that Inspire Medical Systems can reach $300 in the near future.

What are Inspire Medical Systems's analysts' financial forecasts?

Inspire Medical Systems's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $950.74M (high $975.37M, low $929.33M), average EBITDA is $-212M (high $-207M, low $-217M), average net income is $60.22M (high $70.01M, low $49.37M), average SG&A $872.51M (high $895.11M, low $852.86M), and average EPS is $1.97 (high $2.29, low $1.61). INSP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.13B (high $1.15B, low $1.1B), average EBITDA is $-250M (high $-245M, low $-257M), average net income is $98.18M (high $101.33M, low $95.2M), average SG&A $1.03B (high $1.06B, low $1.01B), and average EPS is $3.2 (high $3.31, low $3.11).

Did the INSP's actual financial results beat the analysts' financial forecasts?

Based on Inspire Medical Systems's last annual report (Dec 2023), the company's revenue was $624.8M, beating the average analysts forecast of $597.77M by 4.52%. Apple's EBITDA was $-40.271M, missing the average prediction of $-128M by -68.46%. The company's net income was $-21.153M, missing the average estimation of $-59.575M by -64.49%. Apple's SG&A was $451.96M, missing the average forecast of $524.93M by -13.90%. Lastly, the company's EPS was $-0.0007, missing the average prediction of $-1.863 by -99.96%. In terms of the last quarterly report (Sep 2023), Inspire Medical Systems's revenue was $153.3M, missing the average analysts' forecast of $154.49M by -0.77%. The company's EBITDA was $-13.471M, missing the average prediction of $-34.378M by -60.82%. Inspire Medical Systems's net income was $-8.54M, missing the average estimation of $-17.766M by -51.93%. The company's SG&A was $113.25M, missing the average forecast of $141.78M by -20.12%. Lastly, the company's EPS was $-0.29, missing the average prediction of $-0.58 by -50.00%